000119223 001__ 119223
000119223 005__ 20240228145428.0
000119223 0247_ $$2doi$$a10.1002/pbc.26173
000119223 0247_ $$2pmid$$apmid:27472468
000119223 0247_ $$2ISSN$$a0098-1532
000119223 0247_ $$2ISSN$$a1096-911X
000119223 0247_ $$2ISSN$$a1545-5009
000119223 0247_ $$2ISSN$$a1545-5017
000119223 0247_ $$2altmetric$$aaltmetric:10141492
000119223 037__ $$aDKFZ-2017-00013
000119223 041__ $$aeng
000119223 082__ $$a610
000119223 1001_ $$aBozzai, Barbara$$b0
000119223 245__ $$aAtypical teratoid/rhabdoid tumor arising in a malignant glioma.2
000119223 260__ $$aNew York, NY$$bWiley$$c2017
000119223 3367_ $$2DRIVER$$aarticle
000119223 3367_ $$2DataCite$$aOutput Types/Journal article
000119223 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533813097_16814
000119223 3367_ $$2BibTeX$$aARTICLE
000119223 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119223 3367_ $$00$$2EndNote$$aJournal Article
000119223 520__ $$aAtypical teratoid/rhabdoid tumor (AT/RT), a highly malignant brain tumor in young children, usually arises de novo and has only rarely been described as a secondary malignancy. Here, we present a case of a child with glioblastoma, who was treated postoperatively by a combination of temozolomide, irradiation, and bevacizumab. AT/RT was diagnosed as a secondary tumor, 2.5 years following primary diagnosis. The child died 13 months after the diagnosis of AT/RT. This case demonstrates that malignant gliomas may give rise to AT/RT. It also emphasizes the diagnostic value of a repeated tumor biopsy in the recurrence setting.
000119223 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000119223 588__ $$aDataset connected to CrossRef, PubMed,
000119223 7001_ $$aHasselblatt, Martin$$b1
000119223 7001_ $$aTurányi, Eszter$$b2
000119223 7001_ $$aFrühwald, Michael C$$b3
000119223 7001_ $$aSiebert, Reiner$$b4
000119223 7001_ $$aBens, Susanne$$b5
000119223 7001_ $$aSchneppenheim, Reinhard$$b6
000119223 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b7$$udkfz
000119223 7001_ $$aStelczer, Gábor$$b8
000119223 7001_ $$aHortobágyi, Tibor$$b9
000119223 7001_ $$aHauser, Peter$$b10
000119223 773__ $$0PERI:(DE-600)2130978-4$$a10.1002/pbc.26173$$gVol. 64, no. 1, p. 96 - 99$$n1$$p96 - 99$$tPediatric blood & cancer$$v64$$x1545-5009$$y2017
000119223 909CO $$ooai:inrepo02.dkfz.de:119223$$pVDB
000119223 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000119223 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000119223 9141_ $$y2017
000119223 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119223 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119223 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119223 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPEDIATR BLOOD CANCER : 2015
000119223 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119223 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119223 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119223 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119223 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000119223 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119223 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000119223 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000119223 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000119223 980__ $$ajournal
000119223 980__ $$aVDB
000119223 980__ $$aI:(DE-He78)B062-20160331
000119223 980__ $$aI:(DE-He78)L101-20160331
000119223 980__ $$aUNRESTRICTED